Vogenx, a Phase 2b biotech developing therapies for endocrine and metabolic disorders, raised $81 million by offering 6.3 million shares at $13, the high end of the $11 to $13 range.
VogenX is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases, including post-bariatric hypoglycemia (PBH) and gastroparesis. Its lead candidate, mizagliflozin, is an orally administered, minimally absorbed SGLT1 inhibitor licensed from Kissei Pharmaceutical outside Japan, Korea, and Taiwan. Mizagliflozin has been administered to more than 500 subjects across 10 clinical studies, including two completed Phase 2 PBH studies, and is currently in the Phase 2b EMERGE study. VogenX is also evaluating mizagliflozin in gastroparesis and GIP-dependent Cushing’s syndrome and developing VGX-2857, a preclinical candidate for metabolic indications including weight maintenance.
The Raleigh, NC-based company will trade on the Nasdaq under the symbol VOGX. JonesTrading acted as sole bookrunner on the deal.
